Contrasting Nuvo Pharmaceuticals (OTCMKTS:MRVFF) and Nemus Bioscience (OTCMKTS:NMUS)

Volatility and Risk

Nemus Bioscience has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, Nuvo Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Valuation and Earnings

This table compares Nemus Bioscience and Nuvo Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemus Bioscience	N/A	N/A	-$19.19 million	($0.09)	-7.67
Nuvo Pharmaceuticals	$54.98 million	0.20	-$25.70 million	($0.12)	-8.16

Nemus Bioscience has higher earnings, but lower revenue than Nuvo Pharmaceuticals. Nuvo Pharmaceuticals is trading at a lower price-to-earnings ratio than Nemus Bioscience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nemus Bioscience and Nuvo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemus Bioscience	N/A	N/A	-924.42%
Nuvo Pharmaceuticals	20.88%	-1,996.22%	14.25%

About Nemus Bioscience

Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.

About Nuvo Pharmaceuticals

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.